Latest Recruitment News

EMVision Medical Devices has hit key enrolment milestones in its pivotal brain scanner trial, expanded clinical endpoints, and maintained a strong cash position with $17.1 million on hand.

Freehill Mining’s aggregates business posted a record $1.36 million in quarterly sales, up 47% from the prior quarter, driven by plant improvements and a broadening customer base. June alone saw a record $496,000 in sales, underpinning the company’s copper project ambitions.

Medallion Metals is fast-tracking gold production at its Forrestania Gold Project by launching an Early Production Strategy in Q4 2026, nearly nine months ahead of schedule. This move leverages existing infrastructure to generate cashflow and de-risk the upcoming Ravensthorpe ore processing.

Pantoro Gold's FY2026 gold output fell below expectations due to contractor and labour shortages, prompting a strategic operational review. The company targets 90,000 to 105,000 ounces in FY2027 with a stabilisation-first approach and significant investments in new ore sources and infrastructure.

The a2 Milk Company faced significant supply chain disruptions in its China infant formula segment during late FY26, causing a 14% sales decline in that category. Despite this, overall revenue rose 12% on FY25, supported by strong performances in other product lines and improved margins.

Nexalis Therapeutics has ended funding negotiations with Point8 Capital after failing to secure a formal agreement, while successfully completing its IRX-616a Phase 1 trial with no serious adverse events. The company is reassessing clinical priorities amid funding uncertainty.

Excite Technology Services has raised $3.26 million through a share placement priced at 0.6 cents each, accompanied by free-attaching options pending shareholder approval. The Managing Director will convert $500,000 of debt into equity on matching terms.

Racura Oncology has secured Bellberry HREC approval for its HARNESS-1 lung cancer trial, enabling expansion to additional Australian sites including Chris O’Brien Lifehouse and Austin Health, setting the stage for accelerated patient enrolment.

Telix Pharmaceuticals has gained FDA alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, setting the stage for U.S. enrolment pending regulatory approval.

Aurelia Metals prepares for CEO transition with CFO Martin Cummings stepping in as interim CEO and Leigh Collins appointed interim CFO, ensuring leadership continuity during the search for a permanent CEO.

Imagion Biosystems has raised $3.75 million to fund the start of its Phase 1b/2 clinical trial for the MagSense HER2 imaging agent in the US, following FDA clearance. The capital raising involves a two-tranche share placement with free attaching options, led by CPS Capital.

LTR Pharma’s intranasal spray OROFLOW® has secured ethics approval for a clinical study targeting oesophageal motility disorders, marking its first foray beyond erectile dysfunction. The study, led by Dr Peter Wu, aims to validate a non-invasive alternative for swallowing difficulties in a market projected to reach US$8.1 billion by 2034.